Renal denervation—a valid treatment option despite SYMPLICITY HTN-3

被引：0
|
作者：
Roland E. Schmieder
机构：
[1] Clinical Research Unit of Hypertension and Vascular Medicine,Department of Nephrology and Hypertension
[2] University Hospital Erlangen,undefined
来源：
Nature Reviews Cardiology | 2014年 / 11卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：638 / 638
相关论文
共 50 条
  • [31] Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level?
    Luescher, Thomas F.
    Mahfoud, Felix
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 (26) : 1706 - 1711
  • [32] From SYMPLICITY HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go?
    Pathak, Atul
    Ewen, Sebastian
    Fajadet, Jean
    Honton, Benjamin
    Mahfoud, Felix
    Marco, Jean
    Schlaich, Markus
    Schmieder, Roland
    Tsioufis, Konstantinos
    Ukena, Christian
    Zeller, Thomas
    [J]. EUROINTERVENTION, 2014, 10 (01) : 21 - 23
  • [33] Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence
    Kjeldsen, Sverre E.
    Elmula, Fadl Elmula M. Fadl
    Ingrid, O. S.
    Persu, Alexandre
    Jin, Yu
    Staessen, Jan A.
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2015, 1 (01) : 48 - 56
  • [34] Key questions regarding the SYMPLICITY HTN-3 trial
    Kjeldsen, Sverre E.
    Burnier, Michel
    Narkiewicz, Krzysztof
    Kreutz, Reinhold
    Mancia, Giuseppe
    [J]. LANCET, 2023, 401 (10385): : 1336 - 1337
  • [35] SYMPLICITY HTN-3 results to be announced:a mystery or a story foretold?
    Jan A Staessen
    Yu Jin
    Alexandre Persu
    [J]. The Journal of Biomedical Research, 2014, 28 (02) : 73 - 74
  • [36] SYMPLICITY HTN-3 trial: what is it and what does it mean?
    Boehm, Michael
    Mahfoud, Felix
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 (26) : 1697 - 1698
  • [37] PREFERENTIAL REDUCTION IN MORNING/NOCTURNAL HYPERTENSION BY RENAL DENERVATION FOR DRUG-RESISTANT HYPERTENSION: A NEW ABPM ANALYSIS OF SYMPLICITY HTN-3 AND HTN-JAPAN
    Kario, K.
    Bakris, G. L.
    Bhatt, D.
    [J]. JOURNAL OF HYPERTENSION, 2015, 33 : E52 - E52
  • [38] An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial
    Flack, John M.
    Bhatt, Deepak L.
    Kandzari, David E.
    Brown, David
    Brar, Sandeep
    Choi, James W.
    D'Agostino, Ralph
    East, Cara
    Katzen, Barry T.
    Lee, Lilian
    Leon, Martin B.
    Mauri, Laura
    O'Neill, William W.
    Oparil, Suzanne
    Rocha-Singh, Krishna
    Townsend, Raymond R.
    Bakris, George
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2015, 9 (10) : 769 - 779
  • [39] SYMPLICITY HTN-3 results to be announced: a mystery or a story foretold?
    Staessen, Jan A.
    Jin, Yu
    Persu, Alexandre
    [J]. JOURNAL OF BIOMEDICAL RESEARCH, 2014, 28 (02): : 73 - 74
  • [40] How should data from SYMPLICITY HTN-3 be interpreted?
    Roland E. Schmieder
    [J]. Nature Reviews Cardiology, 2014, 11 : 375 - 376
12345